Access to the PPM Journal and newsletters is FREE for clinicians.

New Sickle Cell Disease Approval

July 8, 2017
Endari enters sickle cell disease arena.

The US Food and Drug Administration (FDA) has announced the approval of the first new product to treat sickcle cell disease in almost 20 years. Endari, from Emmaus Medical, Inc, is a L-glutamine oral powder that reduces  complications of sickle cell disease in patients aged 5 years and older with the disorder.

"Endari is the first treatment approved for patients with sickle cell disease in almost 20 years," Richard Pazdur, MD, acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research and director of the FDA's Oncology Center of Excellence, said in an FDA news release. "Until now, only one other drug was approved for patients living with this serious, debilitating condition."

The decision follows consideration of data from a randomized trial of patients aged 5 to 58 years who had suffered two or more sickle cell pain crises within the 12 months before enrollment in the trial. The researchers randomly assigned patients to receive L-glutamine or placebo. Treatment was evaluated during a 48-week period.

Those who received L-glutamine experienced fewer hospital visits for pain crises that resulted in treatment with parenteral narcotics or ketorolac, on average, compared with those who received placebo (median three vs median four), fewer sickle cell pain hospitalizations (median two vs median three), and fewer hospitalized days (median 6.5 days vs median 11 days).

Those who were given L-glutamine also experienced fewer episodes of acute chest syndrome — a life-threatening sickle cell disease complication — compared with those who were given placebo (8.6% vs 23.1%). Frequent adverse events include constipation, nausea, headache, abdominal pain, cough, extremity pain, back pain, and chest pain.

Approximately 100,000 people in the United States have sickle cell disease, according to the National Institutes of Health. The disease primarily affects African Americans, Latinos, and other minority groups. The average life expectancy for those with sickle cell disease in the United States is 40 to 60 years.

Last updated on: November 5, 2020
Continue Reading:
New Treatment Plan Leads to Better Pain Control for Acute Sickle Cell Crisis

Join The Conversation

Register or Log-in to Join the Conversation
close X